Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA.
Vaccine. 2010 Dec 16;29(2):212-20. doi: 10.1016/j.vaccine.2010.10.053. Epub 2010 Nov 2.
The emergence of Hendra Virus (HeV) and Nipah Virus (NiV) which can cause fatal infections in both animals and humans has triggered a search for an effective vaccine. Here, we have explored the potential for generating an effective humoral immune response to these zoonotic pathogens using an alphavirus-based vaccine platform. Groups of mice were immunized with Venezuelan equine encephalitis virus replicon particles (VRPs) encoding the attachment or fusion glycoproteins of either HeV or NiV. We demonstrate the induction of highly potent cross-reactive neutralizing antibodies to both viruses using this approach. Preliminary study suggested early enhancement in the antibody response with use of a modified version of VRP. Overall, these data suggest that the use of an alphavirus-derived vaccine platform might serve as a viable approach for the development of an effective vaccine against the henipaviruses.
亨德拉病毒(HeV)和尼帕病毒(NiV)的出现能够在动物和人类中引发致命感染,这促使人们寻找一种有效的疫苗。在这里,我们利用基于甲病毒的疫苗平台探索了针对这些人畜共患病病原体产生有效体液免疫应答的潜力。用编码 HeV 或 NiV 的附着或融合糖蛋白的委内瑞拉马脑炎病毒复制子颗粒(VRP)对组小鼠进行免疫。我们证明了使用这种方法可以诱导对两种病毒均具有高度交叉反应性的中和抗体。初步研究表明,使用 VRP 的改良版本可早期增强抗体应答。总体而言,这些数据表明,使用甲病毒衍生的疫苗平台可能成为开发针对亨德拉病毒的有效疫苗的可行方法。